文献速递浆细胞疾病

ALCAM与EGFR相互作用调控骨髓瘤发生

ALCAM-EGFR interaction regulates myelomagenesis.
PubMed 文献 · Blood Adv · 2021-01-01

本研究探讨ALCAM与EGFR相互作用对骨髓瘤发生的调控。ALCAM是骨髓瘤克隆形成的负调控因子,其表达与患者生存正相关;骨髓基质细胞分泌EGF与骨髓瘤细胞EGFR结合激活Mek/Erk、PI3K/Akt及hedgehog通路,而ALCAM可结合EGFR阻断EGF作用。

要点

  • ALCAM是骨髓瘤克隆形成的负调控因子,表达与生存正相关
  • BMSCs分泌EGF经EGFR激活Mek/Erk、PI3K/Akt与hedgehog通路
  • ALCAM结合EGFR阻断EGF信号,抑制骨髓瘤克隆形成

核心结论

  • ALCAM是骨髓瘤发病的新型负调控因子,通过结合EGFR阻断EGF信号。

研究设计与样本

  • 体外细胞实验与患者生存相关性分析。

主要发现

  • ALCAM敲低骨髓瘤细胞在BMSCs存在时集落形成增强。
  • BMSCs分泌EGF结合EGFR激活Mek/Erk、PI3K/Akt与hedgehog通路。
  • ALCAM表达与患者生存正相关,能阻断EGF与EGFR结合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma, a plasma cell malignancy in the bone marrow, remains largely incurable with currently available therapeutics. In this study, we discovered that the activated leukocyte cell adhesion molecule (ALCAM) interacted with epidermal growth factor receptor (EGFR), and regulated myelomagenesis. ALCAM was a negative regulator of myeloma clonogenicity. ALCAM expression was positively correlated with patients' survival. ALCAM-knockdown myeloma cells displayed enhanced colony formation in the presence of bone marrow stromal cells (BMSCs). BMSCs supported myeloma colony formation by secreted epidermal growth factor (EGF), which bound with its receptor (EGFR) on myeloma cells and activated Mek/Erk cell signaling, PI3K/Akt cell signaling, and hedgehog pathway. ALCAM could also bind with EGFR, block EGF from binding to EGFR, and abolish EGFR-initiated cell signaling. Hence, our study identifies ALCAM as a novel negative regulator of myeloma pathogenesis.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Luo H, Zhang D, Wang F, et al. ALCAM-EGFR interaction regulates myelomagenesis. Blood Adv. 2021. PMID: 34592762. doi:10.1182/bloodadvances.2021004695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。